Telix Pharmaceuticals plans to spin off its wholly-owned subsidiary Rhine Pharma and structure it as an independent company.
Rhine Pharma’s mission will be to expand global access to radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m (Tc-99m) and rhenium-188 (Re-188), the company said.
Rhine Pharma was formed through a collaboration between Telix and Heidelberg University Hospital that aimed to develop a ligand that targets prostate cancer that could be labeled with either Tc-99m for SPECT imaging or Re-188 for radioligand therapy. The collaboration resulted in a potential theranostic compound, RHN0014, which the company is now advancing into a phase I/IIa clinical study.
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
